Evotec SE (EVO) Change in Acquisitions & Divestments (2009 - 2026)
Evotec SE (EVO) reported Change in Acquisitions & Divestments of $1059.5 for Q1 2026, down 75.46% on a YoY basis from $4318.0 in Q1 2025, and down 95.44% sequentially from $23243.2 in Q3 2025.
Evotec SE (EVO) Change in Acquisitions & Divestments (2009 - 2026) Analysis & Trends
Evotec SE (EVO) has 8 years of Change in Acquisitions & Divestments data on file, last reported at $1059.5 in Q1 2026.
- For the quarter ending Q1 2026, Change in Acquisitions & Divestments fell 75.46% year-over-year to $1059.5; the trailing twelve-month figure through Mar 2026 stood at $34829.5 (down 7.83% YoY), and the FY2009 full-year result was $33.4 million, changed N/A from the prior year.
- Change in Acquisitions & Divestments eased to $1059.5 in Q1 2026, from $23243.2 in the prior quarter.
- In the past five years, Change in Acquisitions & Divestments ranged from a high of $90238.1 in Q2 2023 to a low of $1059.5 in Q1 2026.
- A 5-year average of $30982.2 and a median of $21720.7 in 2024 frame the typical range for Change in Acquisitions & Divestments.
- Across the five-year window, Change in Acquisitions & Divestments surged 1983.63% in 2022 and slumped 93.89% in 2024, its largest moves.
- Tracing EVO's Change in Acquisitions & Divestments over 5 years: stood at $8099.5 in 2022, then jumped by 467.77% to $45986.4 in 2023, then sank by 86.45% to $6232.4 in 2024, then soared by 272.94% to $23243.2 in 2025, then sank by 95.44% to $1059.5 in 2026.
- Business Quant data shows EVO's Change in Acquisitions & Divestments at $1059.5 in Q1 2026, $23243.2 in Q3 2025, and $6208.8 in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Evotec SE | 351.60 Mn | 351.08 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1,059.52 |
| Mar 31, 2026 | 1,059.52 |
| Sep 30, 2025 | 23,243.15 |
| Sep 30, 2025 | 23,243.15 |
| Jun 30, 2025 | 6,208.80 |
| Jun 30, 2025 | 6,208.80 |
| Mar 31, 2025 | 4,317.99 |
| Mar 31, 2025 | 4,317.99 |
| Sep 30, 2024 | 6,232.40 |
| Sep 30, 2024 | 6,232.40 |
| Jun 30, 2024 | 5,515.82 |
| Jun 30, 2024 | 5,515.82 |
| Mar 31, 2024 | 21,720.72 |
| Mar 31, 2024 | 21,720.72 |
| Sep 30, 2023 | 45,986.42 |
| Sep 30, 2023 | 45,986.42 |
| Jun 30, 2023 | 90,238.08 |
| Jun 30, 2023 | 90,238.08 |
| Mar 31, 2023 | 83,665.92 |
| Mar 31, 2023 | 83,665.92 |